Drawing for CHI

USPTO serial 79367400

CHI

Reviewed by CopyMark Law Group

Reg. 7532471Status 700Registered
Filing date
Status date
Registration date
Oct 15, 2024
Examiner
MANCA, ALBERTO I
Law office
FILE REPOSITORY (FRANCONIA)

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with CHI?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Jeffrey A. Smith

Jeffrey A. Smith Millen White Zelano and Branigan PC2200 Clarendon Blvd Suite 1400Arlington, VA 22201United States

Goods and services

ClassDescriptionStatusFirst use
042Scientific research and development in the field of chemistry, biology and toxicology; scientific and technological services, namely, scientific research and development and technological consulting in the scientific fields of chemistry, biology and toxicology research; research and development relating to scientific and technological services, namely, scientific research in the fields of chemistry, biology and toxicology; research, testing and analysis services, namely, chemical and biological analysis and toxicological testing for research purposes; scientific research in the field of chemistry, biology and toxicology; scientific testing and analysis services in the field of chemistry, biology and toxicology research; computer- aided scientific research in the field of chemistry, biology and toxicology; computer-aided scientific testing and analysis services in the field of chemistry, biology and toxicology research; laboratory research and analysis services in the field of chemistry, biology and toxicology; pharmaceutical research and development services; scientific and technological services, namely, scientific research and development and technological consulting in the field of chemistry, biology and toxicology research; scientific laboratory services in the fields of pharmaceuticals, chemistry, biology and toxicology; scientific analysis services in the field of chemistry, biology and toxicology; scientific and technological services, namely, scientific research and development and technological consulting in the field of chemistry, biology and toxicology research; scientific research in the fields of pharmaceuticals, chemistry, biology and toxicology; chemical and biological analysis for scientific purposes; medical laboratory services, namely, medical laboratory analysis for scientific purposes; providing information on medical and scientific research on pharmaceutical, biological, chemical and agrochemical products; scientific research consulting, namely, preparation of reports in the field of chemistry, biology and toxicology relating to scientific research; providing information relating to technological research in the field of chemistry, biology and toxicology; providing information about industrial analysis and research services in the field of chemistry, biology and toxicology research; provision of information relating to medical, veterinary, chemical and agrochemical research and development; provision of data, namely, providing an online database in the field of medical and chemical research and development; pharmaceutical research consultancy services; pharmaceutical research consulting, namely, consultancy relating to research and development in the field of therapeutics; scientific research consultancy services in the field of chemistry, biology and toxicology; providing technical advice in the field of scientific research in the field of chemistry, biology and toxicology; providing technical advice about industrial research in the field of chemistry, biology and toxicology; consultancy in the field of scientific research in the field of chemistry, biology and toxicology; consulting about industrial research in the field of chemistry, biology and toxicologyACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Apr 12, 2025FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Mar 21, 2025FICSFINAL DISPOSITION NOTICE SENT TO IB—
Mar 21, 2025FIMPFINAL DISPOSITION PROCESSED—
Jan 15, 2025FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Oct 15, 2024NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Oct 15, 2024R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Sep 30, 2024OPNXNOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB—
Sep 11, 2024OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Sep 11, 2024OPNRNOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB—
Jul 30, 2024NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Jul 30, 2024PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jul 10, 2024NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jun 26, 2024CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jun 26, 2024XAECEXAMINER'S AMENDMENT ENTERED—
Jun 26, 2024GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Jun 26, 2024GNEAEXAMINERS AMENDMENT E-MAILED—
Jun 26, 2024CNEAEXAMINERS AMENDMENT -WRITTEN—
May 28, 2024TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
May 28, 2024CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
May 28, 2024TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Dec 19, 2023RFNTREFUSAL PROCESSED BY IB—
Dec 18, 2023TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Dec 18, 2023ECDRTEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS—
Dec 18, 2023ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Dec 18, 2023REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Dec 18, 2023CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Dec 18, 2023COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Nov 29, 2023RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Nov 28, 2023RFRRREFUSAL PROCESSED BY MPU—
Nov 26, 2023RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Nov 25, 2023CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 24, 2023DOCKASSIGNED TO EXAMINER—
Apr 18, 2023MAFRAPPLICATION FILING RECEIPT MAILED—
Apr 14, 2023NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Apr 13, 2023REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance